Chongqing Pharscin Pharmaceutical Co., Ltd. (002907) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Chongqing Pharscin Pharmaceutical Co., Ltd.

Why is Chongqing Pharscin Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of -1.46% and Operating profit at -15.07% over the last 5 years

Flat results in Sep 25

OPERATING CASH FLOW(Y) Lowest at CNY 87.38 MM
OPERATING PROFIT(Q) Lowest at CNY 11.6 MM
OPERATING PROFIT MARGIN(Q) Lowest at 6.36 %

With ROE of 4.51%, it has a expensive valuation with a 4.04 Price to Book Value

Over the past year, while the stock has generated a return of -10.49%, its profits have risen by 117.1% ; the PEG ratio of the company is 0.8
At the current price, the company has a high dividend yield of 0.4

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -10.49% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Chongqing Pharscin Pharmaceutical Co., Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Chongqing Pharscin Pharmaceutical Co., Ltd.

-7.71%

-0.02

40.22%

China Shanghai Composite

13.33%

0.90

14.74%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-1.46%

EBIT Growth (5y)

-15.07%

EBIT to Interest (avg)

23.95

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.32

Sales to Capital Employed (avg)

0.45

Tax Ratio

17.45%

Dividend Payout Ratio

46.27%

Pledged Shares

Institutional Holding

ROCE (avg)

7.58%

ROE (avg)

5.89%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.04

EV to EBIT

98.12

EV to EBITDA

41.57

EV to Capital Employed

5.58

EV to Sales

7.93

PEG Ratio

0.76

Dividend Yield

0.36%

ROCE (Latest)

5.69%

ROE (Latest)

4.51%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -6.8% (YoY

NET PROFIT(9M)

Higher at CNY 71.57 MM

CASH AND EQV(HY)

Highest at CNY 1,200.05 MM

DEBT-EQUITY RATIO (HY)

Lowest at -32.84 %

-4What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at CNY 87.38 MM

OPERATING PROFIT(Q)

Lowest at CNY 11.6 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 6.36 %

Here's what is working for Chongqing Pharscin Pharmaceutical Co., Ltd.

Cash and Eqv

Highest at CNY 1,200.05 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -32.84 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Net Profit

Higher at CNY 71.57 MM

than preceding 12 month period ended Sep 2025

MOJO Watch

In the nine month period the company has already crossed sales of the previous twelve months

Net Profit (CNY MM)

Raw Material Cost

Fallen by -6.8% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Chongqing Pharscin Pharmaceutical Co., Ltd.

Operating Cash Flow

Lowest at CNY 87.38 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Operating Profit

Lowest at CNY 11.6 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at 6.36 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales